文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

High‑dose aflibercept injection has striking effects on myopic choroidal neovascularization.

作者信息

Zhu Wei, Hao Yanlei, Yuan Zhongfang, Huang Chunmei

机构信息

Department of Ophthalmology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250013, P.R. China.

出版信息

Exp Ther Med. 2023 May 9;25(6):301. doi: 10.3892/etm.2023.12000. eCollection 2023 Jun.


DOI:10.3892/etm.2023.12000
PMID:37229317
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10203910/
Abstract

The aim of the present study was to evaluate the 1-year outcomes of a high-dose aflibercept injection [4 mg 2+ pro re nata (PRN) scheme] for individuals with myopic choroidal neovascularization (mCNV) through optical coherence tomography (OCT) follow-ups. A total of 16 consecutive patients (7 males and 9 females; sixteen eyes) with mCNV were enrolled in this retrospective study. The mean age was 30.5±3.35 years and mean spherical equivalent was -7.31±0.90 D. Subjects received 4 mg aflibercept intravitreal injection on the day of diagnosis and 35 days later. Further injections of aflibercept were required when the following were detected by OCT and fluorescein angiography: i) Decrease in best corrected visual acuity (BCVA); ii) aggravation of metamorphopsia; iii) macular oedema; iv) macular haemorrhage; v) increase in retinal thickness; and vi) leakage. Ophthalmic examination and OCT were performed at the baseline, as well as at 1, 2, 4, 6, 8, 10 and 12 months after the initial aflibercept injection. BCVA and central retinal thickness (CRT) were evaluated at each follow-up. The results showed that the vision of all subjects improved following the aflibercept intravitreal injection. The mean BCVA improved from 0.35±0.15 logarithm of the minimal angle of resolution (logMAR) at the baseline to 0.12±0.05 logMAR at final follow-up (P<0.05). A reduction in metamorphopsia was observed and the mean CRT was reduced from 345.38±34.69 µm of pre-treatment levels to 222.75±8.98 µm at the last postoperative visit (P<0.05). The mean number of injections in the present study was 2.13±0.5. Out of all patients, 13 received two injections and 3 subjects received three injections. The mean follow-up was 13.41±1.17 months. Based on the outcomes, it was found that an intravitreal injection of high-dose aflibercept (4 mg 2+PRN scheme) is effective for vision improvement and stabilization. In addition, it also significantly alleviated metamorphopsia and reduced the CRT in patients treated with mCNV. During the follow-up, the eyesight of the patients was stable.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8752/10203910/8402fc4cb9e0/etm-25-06-12000-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8752/10203910/2778788fdf14/etm-25-06-12000-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8752/10203910/7b045b9e780d/etm-25-06-12000-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8752/10203910/8402fc4cb9e0/etm-25-06-12000-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8752/10203910/2778788fdf14/etm-25-06-12000-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8752/10203910/7b045b9e780d/etm-25-06-12000-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8752/10203910/8402fc4cb9e0/etm-25-06-12000-g02.jpg

相似文献

[1]
High‑dose aflibercept injection has striking effects on myopic choroidal neovascularization.

Exp Ther Med. 2023-5-9

[2]
Long-Term Outcomes of High-Dose Conbercept Treatment for Myopic Choroidal Neovascularization and Idiopathic Choroidal Neovascularization.

Ophthalmic Res. 2023

[3]
Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization.

Sci Rep. 2018-9-26

[4]
Retinal vascular changes and aqueous humor cytokines changes after aflibercept intravitreal injection in treatment-naïve myopic choroidal neovascularization.

Sci Rep. 2018-10-23

[5]
Result of intravitreal aflibercept injection for myopic choroidal neovascularization.

BMC Ophthalmol. 2021-9-22

[6]
HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.

Retina. 2018-1

[7]
Intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: a pilot study.

Clin Ophthalmol. 2016-11-4

[8]
Comparison of structural and functional outcome of aflibercept versus ranibizumab in patients with myopic choroidal neovascularization.

Eur J Ophthalmol. 2021-1

[9]
Intravitreal aflibercept for myopic choroidal neovascularization.

Graefes Arch Clin Exp Ophthalmol. 2016-12

[10]
Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.

Graefes Arch Clin Exp Ophthalmol. 2019-4

引用本文的文献

[1]
Prognostic factors for intravitreal conbercept in the treatment of choroidal neovascularization secondary to pathological myopia.

Int Ophthalmol. 2024-6-22

本文引用的文献

[1]
Long-Term Outcomes of High-Dose Conbercept Treatment for Myopic Choroidal Neovascularization and Idiopathic Choroidal Neovascularization.

Ophthalmic Res. 2023

[2]
The efficacy of different anti-vascular endothelial growth factor agents and prognostic biomarkers in monitoring of the treatment for myopic choroidal neovascularization.

Int Ophthalmol. 2022-9

[3]
Comparison of agents using higher dose anti-VEGF therapy for treatment-resistant neovascular age-related macular degeneration.

Graefes Arch Clin Exp Ophthalmol. 2022-7

[4]
Result of intravitreal aflibercept injection for myopic choroidal neovascularization.

BMC Ophthalmol. 2021-9-22

[5]
Anti-VEGF Therapy in Myopic CNV.

Curr Drug Targets. 2021

[6]
Three-year real-world outcomes of intravitreal anti-VEGF therapies in patients affected by myopic choroidal neovascularization.

Eur J Ophthalmol. 2021-9

[7]
Comparison of Efficacy of Intravitreal Ranibizumab and Aflibercept in Eyes with Myopic Choroidal Neovascularization: 24-Month Follow-Up.

J Ocul Pharmacol Ther. 2020-3

[8]
Comparison of structural and functional outcome of aflibercept versus ranibizumab in patients with myopic choroidal neovascularization.

Eur J Ophthalmol. 2021-1

[9]
Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization.

Sci Rep. 2018-9-26

[10]
HIGH-DOSE HIGH-FREQUENCY AFLIBERCEPT FOR RECALCITRANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

Retina. 2018-6

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索